Search
Cardiff Oncology Inc
CRDFAdd to Watchlist
0.928USD
-0.011-1.17%
Close 10-22 16:00（ET）
72.20MMarket Cap
LossP/E TTM
Pre-market 07:04 (ET)0.920USD-0.008-0.86%
Pre-market 07:04 (ET)Cardiff Oncology Inc (CRDF) Stock Price Target & Forecast
Analyst Rating
Based on 6 analysts giving stock ratings to Cardiff Oncology Inc in the past month.
Buy
0 Strong Buy
3 Buy
3 Hold
0 Sell
0 Strong Sell
Target Price
7.300USD+710.12%
CRDF Analyst Recommendation Trends
In the current month, CRDF has received 3 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. CRDF average Analyst price target in the last month is 7.300.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
0
0
1
1
1
1
1
1
3
3
3
3
6
6
6
6
3
3
4
4
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6
6
8
8
8
8
8
8
CRDF Analyst Rating for Peer Comparison
Updated: Oct 20, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
argenx SE
ARGX
10
14
3
0
0
27
Insmed Inc
INSM
7
18
0
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
Ionis Pharmaceuticals Inc
IONS
6
14
5
0
0
25
Biontech SE
BNTX
4
12
8
0
0
24
Kymera Therapeutics Inc
KYMR
9
13
2
0
0
24
IQVIA Holdings Inc
IQV
8
12
3
0
0
23
Cytokinetics Inc
CYTK
5
16
2
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Financial Forecasting
Based on analysts' estimates, CRDF EPS is projected to reach -0.150 in FY2026Q3, following reported EPS of -0.135 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.19
-0.13
-0.16
-0.15
-0.16
Actual
-0.11
-0.18
-0.14
--
--
Surprise
+43.02%
-34.22%
+16.24%
--
--
FAQs
What is Cardiff Oncology Inc's expected revenue for the next quarter?
Cardiff Oncology Inc's expected revenue is 79.17K.
What is Cardiff Oncology Inc's price target?
Analysts forecast that Cardiff Oncology Inc's price target is USD 7.30, with the highest forecast at USD 12.00 and the lowest forecast at USD 2.00.
How have Cardiff Oncology IncCRDF's recent earnings per share performed?
The market expectation was USD -0.14, while Cardiff Oncology IncCRDF's earnings per share (EPS) for the previous quarter was USD -0.18. EPS for the next quarter is expected at USD -0.15.
What is the analyst rating for Cardiff Oncology Inc?
Based on the ratings of Cardiff Oncology Inc's stock from 6 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.